Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea’s Bukwang To Sell Hepatitis B Drug In Philippines, Plans Launches In U.S., Europe   

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Bukwang Pharmaceutical will begin selling its chronic hepatitis B drug Levovir (clevudine) in the Philippines in June, and plans to eventually launch the product across Asia, the U.S. and Europe, according to a company executive

You may also be interested in...



Korea's Yuhan Signs Deal To Sell Gilead's Viread In Korea

SEOUL - South Korea's Yuhan Corp. said it signed an agreement March 30 with Gilead Sciences Inc. to sell the latter's hepatitis B drug Viread (tenofovir) in Korea, beginning in the second half of this year after winning approval from Korea FDA

Korea's Yuhan Signs Deal To Sell Gilead's Viread In Korea

SEOUL - South Korea's Yuhan Corp. said it signed an agreement March 30 with Gilead Sciences Inc. to sell the latter's hepatitis B drug Viread (tenofovir) in Korea, beginning in the second half of this year after winning approval from Korea FDA

Korean Govt Asks MNCs For More Hepatitis A Vaccines

SEOUL - Alarmed by the rapidly rising demand for hepatitis A vaccines to treat students and office workers with the virus, South Korea's Center for Disease Control and Prevention is calling on four multinational companies to bring more vaccines to Korea

Related Content

UsernamePublicRestriction

Register

SC018508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel